Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 192Methotrexate 106Cytarabine 86fludarabine phosphate 80Busulfan 71Tacrolimus 70Peripheral Blood Stem Cell Transplantation 69Mycophenolic Acid 69Whole-Body Irradiation 68Vincristine 67fludarabine 61Filgrastim 61Etoposide 59Dexamethasone 54Melphalan 52Radiotherapy 47Rituximab 46Cyclosporine 46Doxorubicin 38Antilymphocyte Serum 37Thiotepa 35Prednisone 35Mercaptopurine 35Granulocyte Colony-Stimulating Factor 35blinatumomab 33pegaspargase 27Methylprednisolone 27Daunorubicin 26Clofarabine 26Asparaginase 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × lorvotuzumab mertansine × Clear all
NCT02420873 2018-08-28

An Open-label Phase II Study of Lorvotuzumab Mertansine

M.D. Anderson Cancer Center

Phase 2 Completed
9 enrolled 7 charts
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡